The role of miRNA -181C between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients

Abstract

BackgroundThe development of cancer is just one of the many effects of dysregulation of miRNA expression patterns, miRNA have been found to express abnormally in hematological neoplasia such as chronic myeloid leukemia and solid malignancies. Resistance and the degree of response following TKI treatment are correlated with miRNA expression. Hence, in this study we tried to study the relationship of miRNA- 181c between different p210 BCR-ABL transcript levels and the role miRNA-181c between different levels of imatinib optimal response in CML. MethodOur study included sixty CML patients they were divided into two groups based on response to imatinib therapy, thirty samples optimal molecular response of CML patients and thirty samples of failure molecular response CML patients. Thirty samples of apparently healthy volunteers were included and evaluated as control. ResultsAccording the P210 BCR-ABL% results there was a significant difference (P ≤ 0.0001), between the responder and the failure response CML patients, assessed the expression of the level miRNA-181c the result showed high significant difference between both CML patients groups (P = 0.0012). Assessed the expression of the level miRNA-181c in different responses and failure response of CML patients, there was a significant difference of miRNA-181c level among different responses groups and failure response of CML patients (P = 0.0044). A cutoff value of response vs. failure response (7.24) with high sensitivity can be of diagnostic value to differentiate between response and failure response. ConclusionChanging gene expression with different amounts of miRNAs has an impact on drug-gene interactions, with consequences for cell growth and death. Gene expression different level miRNA-181c among of CML patients of imatinib therapy were high expression in response patients than failure response patients. The gene expression level of miRNA-181c differs between through different response CML patients.